R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
This is a prospective clinical study to evaluate the safety and efficacy of R-CMOP in patients with newly diagnosed diffuse large B-cell lymphoma
Trial Details
- NCT ID
- NCT06594640
- Phase
- PHASE1 / PHASE2
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- RECRUITING
- Cancer Type
- Lymphoma
- Interventions
- Mitoxantrone Hydrochloride Liposome
- Rituximab (R)
- Cyclophosphamide (CTX)
- Vincristin
- Prednisolone
- Locations (sample)
- Tianjin, Tianjin Municipality, China|39.14222,117.17667
Key Eligibility Criteria
- Age ≥18 years;
- Histologically confirmed newly diagnosed diffuse large B-cell lymphoma;
- Patients must have been untreated, including chemotherapy, targeted therapy, immunotherapy, radiotherapy;
- There must be at least one measurable lesion per the Lugano2014 criteria；
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →